Schrödinger (SDGR) Projected to Post Earnings on Wednesday
Schrödinger (NASDAQ:SDGR) is set to announce its earnings on February 26, with expectations of a loss of $0.35 per share and revenue of $83.20 million. The stock opened at $22.64, with a market cap of $1.65 billion. Analysts have a consensus rating of "Moderate Buy" and a target price of $32.11. Recent upgrades include BMO Capital Markets raising its target from $25 to $28 and KeyCorp from $25 to $27. Investors can join the conference call via a provided link.
Schrödinger (NASDAQ:SDGR - Get Free Report) is anticipated to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $83.20 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Schrödinger Price Performance
- AI Pharma: 2 Paths to AI-Powered Drug Investment
Shares of NASDAQ SDGR opened at $22.64 on Monday. The stock has a market capitalization of $1.65 billion, a PE ratio of -9.68 and a beta of 1.61. The business has a fifty day moving average price of $22.19 and a two-hundred day moving average price of $20.52. Schrödinger has a fifty-two week low of $16.67 and a fifty-two week high of $33.63.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on SDGR. BMO Capital Markets boosted their price target on Schrödinger from $25.00 to $28.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. KeyCorp boosted their price target on Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.11.
- Simulations Plus Stock Drops 15% Despite EPS Beat
View Our Latest Research Report on Schrödinger
About Schrödinger
(Get Free Report)Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Featured Stories
- Five stocks we like better than Schrödinger
- Earnings Per Share Calculator: How to Calculate EPS
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- What is the Australian Securities Exchange (ASX)
- These 5 Energy Stocks Hedge Inflation With Growth Potential
- Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Schrödinger Right Now?
Before you consider Schrödinger, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrödinger wasn't on the list.
While Schrödinger currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
